The discovery that cancer cells can hijack normal lactate metabolism to create treatment-resistant states represents a fundamental shift in understanding tumor survival strategies. Rather than being merely metabolic waste, lactate now emerges as a molecular architect of cancer persistence through a process called protein lactylation. This mechanism transforms lactate into covalent protein modifications that simultaneously shield tumors from therapy while potentially exposing new therapeutic vulnerabilities. The research reveals lactylation operates through multiple enzymatic pathways including AARS1/2, KATs, and HDACs, alongside non-enzymatic routes involving MGO/LGSH compounds. These modifications target both histone and non-histone proteins, fundamentally altering their structure and function. Particularly striking is the disruption of p53 tumor suppressor activity and enhancement of DNA repair proteins like XLF, creating a cellular environment primed for survival under therapeutic stress. The process exhibits sophisticated crosstalk with other protein modifications, exemplified by the synergistic interaction between H3K18 lactylation and H3K27 acetylation in T-cell leukemia. This represents a paradigm shift from viewing cancer metabolism as simply altered energy production to recognizing it as an active epigenetic regulatory system. The dual nature of lactylation-driven resistance encompasses both intrinsic mechanisms like BLM K24la-mediated DNA repair enhancement and extrinsic immune evasion through PD-L1 upregulation. However, this same dependency creates therapeutic opportunities, with preclinical studies showing promise for LDHA inhibitors like stiripentol and targeted KAT blockers. The identification of lactylation as a metabolic-epigenetic switch suggests cancer's adaptive advantage may simultaneously represent its greatest vulnerability when properly targeted.